Clinical Trials

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04435691 2026-04-23

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

110 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT04284787 2026-04-13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

60 enrolled 11 charts

Leukemia, Myeloid, Acute

NCT03466294 2026-04-09

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

42 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT04102020 2026-04-08

VIALE-M

112 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

5 enrolled 10 charts

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

75 enrolled 14 charts

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

130 enrolled 38 charts

Leukemia, Leukemia, Myeloid, Acute

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04150029 2026-01-13

STIMULUS-AML1

Phase 2 Terminated

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01869114 2025-12-10

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

57 enrolled 13 charts

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 2 FDA

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 1 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

MyeloidOther hematologic neoplasmThoracic

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT03268954 2025-10-29

PANTHER

454 enrolled 41 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

70 enrolled 14 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

24 enrolled 16 charts

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05168202 2025-09-25

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

56 enrolled 24 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

183 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT04023526 2025-08-20

CULMINATE

103 enrolled 19 charts

Leukemia, Myeloid, Acute

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

100 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02269280 2025-08-07

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

185 enrolled 12 charts

Leukemia, Myelodysplastic Syndromes

NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

7 enrolled 16 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02675452 2025-07-09

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasmPlasma cell

141 enrolled 46 charts

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

472 enrolled 24 charts 1 FDA

336 enrolled 48 charts 1 FDA

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Phase 1/2 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

LymphoidMyeloidOther hematologic neoplasm

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00629343 2025-06-05

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Other solid neoplasmSarcomaThoracic

27 enrolled 7 charts

Mesothelioma, Sarcoma

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

LymphoidMyeloidOther hematologic neoplasm

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02577406 2025-05-18

IDHENTIFY

319 enrolled 29 charts

Leukemia, Leukemia, Myeloid

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

58 enrolled 16 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

21 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03813147 2025-04-13

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

12 enrolled 16 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01892371 2025-04-06

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1/2 Completed

73 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Leukemia, Myeloid, Acute

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Phase 2 Terminated

54 enrolled 26 charts

Myeloid Malignancies

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

154 enrolled 10 charts

MDS

NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

33 enrolled 7 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

51 enrolled 9 charts

Myeloid Malignancy

NCT02828358 2025-02-27

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement